May 24, 2010 - NormOxys Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body’s ability to deliver oxygen to diseased tissues, announced that it has initiated a Phase 1 clinical trial of OXY111A, a novel allosteric modulator of affinity of oxygen to hemoglobin. NormOxys plans to initially develop this compound as a treatment for chronic heart failure and cancer indications. The Phase 1 trial will evaluate OXY111A in healthy volunteers at escalating dose levels.The randomized, single-blind, ascending dose design will assess the safety, tolerability and pharmacokinetics of single intravenous doses of OXY111A in healthy volunteers. Biomarkers in this study include the measurement of P50, which evaluates the proof of pharmacology by quantifying changes in oxygen affinity produced by OXY111A as well as cardiopulmonary exercise testing to assess clinical improvements in oxygen delivery. Following this study will be safety and efficacy studies in chronic heart failure and oncology indications... [PDF] NormOxys' Press Release -
